About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by 23andMe, Inc.

< Previous 1 2 Next >
TTAM Research Institute, A Nonprofit Public Benefit Corporation, Completes The Acquisition of 23andMe Assets
From 23andMe, Inc.
Via GlobeNewswire
Tickers MEHCQ
23andMe Receives Court Approval for Sale to TTAM Research Institute, a Nonprofit Public Benefit Corporation
From 23andMe, Inc.
Via GlobeNewswire
Tickers MEHCQ
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
From 23andMe, Inc.
Via GlobeNewswire
Tickers MEHCQ REGN
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
From 23andMe, Inc.
Via GlobeNewswire
Tickers MEHCQ
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
From 23andMe, Inc.
Via GlobeNewswire
Tickers MEHCQ REGN
23andMe Provides Update Regarding Court-Supervised Sale Process
From 23andMe, Inc.
Via GlobeNewswire
Tickers MEHCQ
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Launches New Genetic Report on Osteoporosis
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Special Committee Announces Exploration of Strategic Alternatives
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Regains Compliance With Nasdaq Listing Requirements
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Appoints Three New Independent Directors to Board
From 23andMe, Inc.
Via GlobeNewswire
Tickers ANSS CDLX LSCC ME
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces Completion of 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Announces Mathew Knowles as New Brand Ambassador
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
Independent Directors of 23andMe Resign from Board
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
From 23andMe, Inc.
Via GlobeNewswire
Tickers ME
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.